---
title: "Canaan Partners Leads Vedana Therapeutics Series A"
description: "Canaan Partners led a Series A for Vedana Therapeutics, extending the firm’s healthcare franchise as it deploys its $850M Fund XIII."
date: 2026-06-16T00:00:00.000Z
tags: ["canaan-partners", "series-a", "healthcare", "biotech", "startup-funding"]
source: https://venturecapitaltracker.com/2026-canaan-partners-vedana-therapeutics-series-a
---

# Canaan Partners Leads Vedana Therapeutics Series A

> Canaan Partners led a Series A for Vedana Therapeutics, extending the firm’s healthcare franchise as it deploys its $850M Fund XIII.

**Canaan Partners** led a **Series A for Vedana Therapeutics** in June 2026, extending the firm's healthcare franchise as it actively deploys its $850M Fund XIII.

## Key facts

- **Lead investor:** Canaan Partners
- **Company:** Vedana Therapeutics (biopharma)
- **Round:** Series A
- **Date:** June 2026
- **Fund:** Canaan XIII ($850M, April 2023); ~$6.8B total AUM
- **Track record:** 73 IPOs and 152 M&As across 35+ years

## Why this matters

Vedana reflects Canaan Partners' long-standing healthcare practice (Day One Biopharmaceuticals, IDEAYA, Synthekine) alongside its technology investing, all from the same multi-generation platform.

## Sources

1. Canaan Partners portfolio (Caplight): https://www.caplight.com/investor/canaan
2. Canaan XIII $850M announcement: https://canaan.com/latest/announcing-canaan-xiii